PharmaVoice 12 févr. 2026 Lilly’s $2.4B bet on off-the-shelf cell therapy is part of a wider Big Pharma shift
BioPharma Dive 9 févr. 2026 Lilly buys ‘in vivo’ CAR-T maker Orna, extending streak of genetic medicine deals
FierceBiotech 9 févr. 2026 Lilly, Innovent pen $8.8B oncology, immunology collab that 'moves beyond traditional licensing'
FierceBiotech 4 févr. 2026 Lilly drops 3 pipeline drugs, including gene therapy, from $1B Prevail buyout
BioPharma Dive 4 févr. 2026 Lilly soars again as fast-selling weight loss drugs top Wall Street projections
PharmaVoice 29 janv. 2026 Eli Lilly, BioAge chase NLRP3 inhibitors with ‘pipeline in a pill’ potential
FierceBiotech 29 janv. 2026 Repertoire adds Lilly to range of Big Pharma partners in autoimmune deal worth up to $2.69B